Brief: Arch Provides Interim Update On Phase I Trial For Metablok (Lsalt Peptide)
07/11/2019 12:29
Arch Biopartners Inc ARCH.V :
* ARCH PROVIDES INTERIM UPDATE ON PHASE I TRIAL FOR METABLOK
(LSALT PEPTIDE)
* ARCH BIOPARTNERS- LEAD METABLOK CANDIDATE HAS MET PRIMARY
ENDPOINTS IN TRIAL'S THREE SINGLE ASCENDING DOSE COHORTS OF
HEALTHY VOLUNTEERS
* ARCH BIOPARTNERS- SECOND PART OF STUDY IS EXPECTED TO BE
COMPLETED BY END OF NOVEMBER
Source text for Eikon: ID:nGNXc8Rk7Z
Further company coverage: ARCH.V
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide